Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Capital Expenditures (2016 - 2025)

Standard Biotools (LAB) has disclosed Capital Expenditures for 16 consecutive years, with -$7.0 million as the latest value for Q4 2025.

  • Quarterly Capital Expenditures fell 306.27% to -$7.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $851000.0 through Dec 2025, down 89.81% year-over-year, with the annual reading at $851000.0 for FY2025, 89.81% down from the prior year.
  • Capital Expenditures for Q4 2025 was -$7.0 million at Standard Biotools, down from $7.6 million in the prior quarter.
  • The five-year high for Capital Expenditures was $12.8 million in Q3 2021, with the low at -$7.0 million in Q4 2025.
  • Average Capital Expenditures over 5 years is $2.2 million, with a median of $921500.0 recorded in 2022.
  • The sharpest move saw Capital Expenditures surged 3676.11% in 2021, then crashed 523.69% in 2025.
  • Over 5 years, Capital Expenditures stood at $500000.0 in 2021, then surged by 51.0% to $755000.0 in 2022, then plummeted by 464.64% to -$2.8 million in 2023, then skyrocketed by 222.85% to $3.4 million in 2024, then tumbled by 306.27% to -$7.0 million in 2025.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at -$7.0 million, $7.6 million, and -$4.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.